Moderate-Flow Perfusion is Superior to Low-Flow Perfusion in Ex Situ Lung Perfusion
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.08.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Keir Forgie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart …. Hauptthemen laut MEDLINE: Perfusion, Lung Transplantation, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Full-flow perfusion during prolonged ex situ lung perfusion (ESLP) results in unacceptable pulmonary edema formation. Clinical ESLP at 30% to 50% predicted cardiac output (CO) supports acceptable physiologic outcomes; however, progressive pulmonary edema still develops. Lower flow rates may provide equivalent physiologic preservation with less edema formation due to reduced hydrostatic pressures. We report our results of moderate-flow (MF; 30% CO) vs low-flow (LF; 10% CO) negative pressure ventilation (NPV)-ESLP with transplantation. METHODS: Twelve pig lungs underwent 12-hours of NPV-ESLP with 30% or 10% CO (n = 6/group). Three left lungs per group were transplanted post-ESLP and assessed in vivo over 4 hours. Lung function was assessed by physiologic parameters, weight-gain, and pro-inflammatory cytokine profiles. RESULTS: Results are MF vs LF (mean ± SEM). All lungs demonstrated acceptable oxygenation post-ESLP (454.2 ± 40.85 vs 422.7 ± 31.68, P = .28); however, after transplantation, the MF lungs demonstrated significantly better oxygenation (300.7 ± 52.26 vs 141.9 ± 36.75, P = .03). There was no significant difference in compliance after ESLP (21.38 ± 2.28 vs 16.48 ± 2.34, P = .08); however, pulmonary artery pressure (PAP; 10.89 ± 2.28 vs 21.11 ± 0.93, P = .06) and pulmonary vascular resistance (PVR; 438.60 ± 97.97 vs 782.20 ± 162.20, P = .05) were significantly higher in the LF group. Weight gain (%) post-ESLP and post-transplant was similar between groups (29.42 ± 5.72 vs 24.17 ± 4.42, P = .24; and 29.63 ± 7.23 vs 57.04 ± 15.78, P = .09). TNF-α and IL-6 were significantly greater throughout LF ESLP. CONCLUSIONS: The MF NPV-ESLP results in superior lung function with less inflammation compared to LF NPV-ESLP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
- Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Ray Rajotte Surgical Medical Research Institute (SMRI) , Edmonton, AB, Canada.
- Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada; Alberta Transplant Institute, Ed…
Zitieren
APA
Forgie, K., Fialka, N., Watkins, A., Du, K., Himmat, S., Hatami, S., Khan, M., Wang, X., Edgar, R., Buswell-Zuk, K. M., Freed, D., & Nagendran, J. (2024). Moderate-Flow Perfusion is Superior to Low-Flow Perfusion in Ex Situ Lung Perfusion. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.08.032
Vancouver
Forgie K, Fialka N, Watkins A, Du K, Himmat S, Hatami S, et al. Moderate-Flow Perfusion is Superior to Low-Flow Perfusion in Ex Situ Lung Perfusion. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.08.032
BibTeX
@article{Forgie2024,
author = {Forgie, Keir and Fialka, Nicholas and Watkins, Abeline and Du, Katie and Himmat, Sayed and Hatami, Sanaz and Khan, Mubashir and Wang, Xiuhua and Edgar, Ryan and Buswell-Zuk, Katie-Marie and Freed, Darren and Nagendran, Jayan},
title = {Moderate-Flow Perfusion is Superior to Low-Flow Perfusion in Ex Situ Lung Perfusion},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.08.032}
}
EUVIMED